CDC25A (Ab-178) Antibody

What is CDC25A and what role does it play in cell cycle regulation?

CDC25A is a dual-specificity phosphatase that functions as a key regulator of the cell cycle. It was initially described as a protein required for progression through mitosis that could be activated by Cyclin B-containing complexes but not by Cyclin A-containing complexes . CDC25A primarily functions by removing inhibitory phosphorylations from cyclin-dependent kinases (CDKs), thereby activating these kinases and promoting cell cycle progression.

The protein contains multiple functional domains including an N-terminal regulatory domain (amino acids 1-335), a catalytic domain (amino acids 335-495), and a C-terminal domain (amino acids 495-523) . CDC25A's activity is tightly regulated through various mechanisms including phosphorylation, protein-protein interactions, and subcellular localization to ensure proper timing of cell cycle events. RNA interference (RNAi) experiments have demonstrated that reducing CDC25A levels delays mitotic entry, confirming its essential role in cell cycle control .

What applications is the CDC25A (Ab-178) antibody suitable for?

The CDC25A (Ab-178) antibody can be utilized for various research applications in the investigation of cell cycle regulation and cancer biology. While specific information about the Ab-178 clone is limited in the provided search results, CDC25A antibodies generally support Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence/immunocytochemistry (IF/ICC) applications .

These applications allow researchers to:

• Detect CDC25A protein expression levels in cell and tissue lysates (WB)

• Visualize CDC25A localization in fixed tissue sections (IHC)

• Examine the subcellular distribution of CDC25A in cultured cells (IF/ICC)

Each application requires optimization of antibody dilution and experimental conditions, which should be determined empirically by the researcher based on their specific experimental system .

How can I determine the optimal working dilution for CDC25A antibody in my experiments?

Determining the optimal working dilution for CDC25A antibody requires systematic testing across a range of concentrations for your specific application and biological system. Begin with the manufacturer's recommended dilution range and perform a dilution series (e.g., 1:250, 1:500, 1:1000, 1:2000) for your particular application (WB, IHC, or IF/ICC) .

For Western blotting, evaluate signal-to-noise ratio at each dilution, looking for strong specific bands at the expected molecular weight (~59 kDa for CDC25A) with minimal background. For immunohistochemistry and immunofluorescence, assess both signal intensity and background staining in positive control samples known to express CDC25A.

Include appropriate negative controls (samples without CDC25A expression or primary antibody omission controls) to verify specificity. Document the conditions that provide the optimal balance between specific signal strength and minimal background for future reference. Remember that optimal dilutions may vary between different experimental conditions and sample types.

What conjugation options are available for CDC25A (Ab-178) antibody?

The CDC25A (Ab-178) antibody can be custom conjugated with a wide variety of labels to suit different experimental needs . According to AAT Bioquest, available conjugation options include:

These conjugation options provide flexibility for various applications including flow cytometry, fluorescence microscopy, ELISA, and other immunodetection methods. Selection should be based on the specific requirements of your experimental setup, including available instrumentation, multiplexing needs, and target sensitivity requirements .

How does CDC25A structurally interact with its CDK-cyclin substrates?

Recent cryo-EM studies have provided significant insights into the structural basis of CDC25A interaction with its substrates. The structure of CDK2-cyclin A in complex with CDC25A at 2.91 Å resolution reveals the precise binding mode between these proteins .

CDC25A's catalytic domain binds across both the N- and C-terminal lobes of CDK2, creating a specific interaction interface that positions the phosphatase active site to access the inhibitory phosphorylation sites on CDK2. The structure revealed a previously unobserved C-terminal helix in CDC25A that binds at the interface between CDK2 and cyclin A .

The CDC25A catalytic domain (amino acids 335-495) contains the active site cysteine (C431) that is critical for its phosphatase activity. The structure shows how this domain is positioned to dephosphorylate key regulatory sites on CDK2, particularly threonine 14 and tyrosine 15, which must be dephosphorylated for CDK activation .

Understanding these structural interactions provides mechanistic insights into how CDC25A recognizes and activates its substrates, information that could potentially be leveraged for the development of specific inhibitors or activators of this pathway.

What is the relationship between CDC25A and CDC25B in regulating mitotic entry?

CDC25A and CDC25B demonstrate a cooperative relationship in regulating mitotic entry, with distinct yet overlapping functions in cell cycle control. Research using RNA interference (RNAi) has shown that reducing levels of either CDC25A or CDC25B, but not CDC25C, delays mitotic entry. Significantly, cells treated with siRNA targeting both CDC25A and CDC25B simultaneously were completely blocked in the G2 phase, unable to enter mitosis .

This indicates that CDC25A and CDC25B cooperate to induce mitosis, with each phosphatase potentially regulating different aspects of the process. Time-lapse microscopy studies suggest that while CDC25A primarily regulates nuclear events during mitotic entry, CDC25B appears to regulate events in both the nucleus and cytoplasm .

Specifically, CDC25B plays a critical role in activating Cyclin B1/Cdk1 complexes at the centrosomes during early mitotic events. Cells with reduced CDC25B levels show higher amounts of phosphorylated (inactive) Cyclin B1/Cdk1 on unseparated centrosomes compared to control cells. This indicates that CDC25B is required for the initial activation of Cyclin B1/Cdk1 at centrosomes, which serves as a trigger for subsequent activation throughout the cell .

The spatial and temporal coordination between CDC25A and CDC25B activities appears essential for proper mitotic progression, with CDC25B potentially initiating activation at centrosomes and CDC25A amplifying the signal, particularly in the nucleus.

How does subcellular localization affect CDC25A function in cell cycle regulation?

The subcellular localization of CDC25A is a critical regulatory mechanism that impacts its function in cell cycle control. CDC25A contains specific localization signals that regulate its distribution between the nucleus and cytoplasm, including a nuclear localization signal (NLS) that has been identified .

The spatial regulation of CDC25A is important because it determines which pool of CDK-cyclin complexes the phosphatase can activate. For instance, during mitotic entry, active Cyclin B1/Cdk1 complexes first appear at the centrosomes before spreading to the cytoplasm and eventually translocating to the nucleus . The appropriate localization of CDC25 phosphatases at these different cellular compartments is necessary for the proper spatiotemporal activation of CDK-cyclin complexes.

Understanding the mechanisms controlling CDC25A localization provides insights into how cells coordinate CDK activation in different cellular compartments during cell cycle progression and in response to cellular stresses.

What methodological considerations are important when using CDC25A antibodies to study phosphorylation-dependent events?

When using CDC25A antibodies to study phosphorylation-dependent events, several methodological considerations are crucial for generating reliable and interpretable results:

• Phosphorylation state preservation: CDC25A itself is regulated by phosphorylation, with sites such as Ser178 and Thr507 being particularly important . To accurately assess CDC25A phosphorylation status, samples must be collected and processed with phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) to prevent post-lysis dephosphorylation.

• Phospho-specific antibodies: When studying CDK dephosphorylation by CDC25A, consider using phospho-specific antibodies that recognize the inhibitory phosphorylations on CDKs (such as pT14/pY15 on CDK2). These can provide direct evidence of CDC25A activity by monitoring substrate phosphorylation status.

• Temporal considerations: CDC25A activity fluctuates throughout the cell cycle. Therefore, cell synchronization techniques may be necessary to examine CDC25A function at specific cell cycle phases. Methods such as double thymidine block, nocodazole arrest, or selective CDK inhibitors can be used to enrich cells at particular cell cycle stages.

• Detergent selection for immunoprecipitation: When studying CDC25A-substrate interactions, the choice of detergent can significantly impact results. For instance, the use of CHAPS as a detergent improved the variety of 2D class averages in cryo-EM studies of CDC25A-CDK2-cyclin A complexes , suggesting that mild detergents may better preserve protein-protein interactions.

• Controls for antibody specificity: Include appropriate controls such as CDC25A knockdown or knockout samples to verify antibody specificity. This is particularly important when studying closely related family members (CDC25A, B, and C) that share sequence homology.

What are the best practices for optimizing Western blotting using CDC25A antibodies?

Optimizing Western blotting for CDC25A detection requires attention to several technical considerations:

How can I effectively utilize CDC25A antibodies in immunofluorescence studies to track subcellular localization?

Effective utilization of CDC25A antibodies for immunofluorescence studies to track subcellular localization requires careful consideration of several methodological aspects:

• Fixation method: The choice between paraformaldehyde (PFA), methanol, or other fixatives can significantly impact epitope accessibility. For CDC25A, 4% PFA fixation for 10-15 minutes at room temperature is often effective, but comparative testing with methanol fixation may be necessary to determine optimal conditions for your specific antibody.

• Permeabilization: After fixation with PFA, permeabilization with 0.1-0.5% Triton X-100 or 0.05% saponin is typically required to allow antibody access to intracellular CDC25A. The concentration and duration should be optimized to balance antibody accessibility with preservation of cellular structures.

• Blocking: Use 5-10% normal serum (from the species in which the secondary antibody was raised) in PBS with 0.1% Triton X-100 to reduce nonspecific binding. Alternatively, 1-3% BSA can be effective.

• Antibody dilution: Start with the manufacturer's recommended dilution for IF/ICC applications , typically in the range of 1:100 to 1:500, and optimize through serial dilutions.

• Co-localization markers: Include antibodies against organelle markers to precisely determine CDC25A subcellular localization. For example:

  • Nuclear markers: DAPI or Hoechst for DNA, lamin antibodies for nuclear envelope

  • Centrosomal markers: γ-tubulin, pericentrin

  • Cytoplasmic markers: α-tubulin for microtubules

• Cell cycle markers: Since CDC25A localization may change throughout the cell cycle, consider co-staining with cell cycle phase markers such as:

  • Cyclin E or PCNA for S phase

  • Phospho-histone H3 for mitosis

  • Cyclin B1 for G2/M transition

• Image acquisition: Use confocal microscopy for accurate determination of subcellular localization. Z-stacks should be collected to capture the three-dimensional distribution of CDC25A within cells.

• Quantification: Develop a quantitative approach to assess CDC25A distribution, such as measuring nuclear/cytoplasmic intensity ratios across multiple cells under different conditions or treatments.

• Controls: Include appropriate controls such as primary antibody omission, CDC25A knockdown cells, and comparative staining with antibodies against related family members (CDC25B, CDC25C) to ensure specificity.

What experimental approaches can be used to study CDC25A-mediated CDK activation?

Several experimental approaches can be employed to study CDC25A-mediated CDK activation, each providing complementary insights:

• In vitro phosphatase assays: Recombinant CDC25A can be used to dephosphorylate purified, inactive (phosphorylated) CDK-cyclin complexes in vitro. The dephosphorylation can be monitored by:

  • Western blotting with phospho-specific antibodies against inhibitory CDK phosphorylations (e.g., pT14/pY15)

  • CDK kinase activity assays using model substrates such as histone H1

  • Mass spectrometry to quantitatively measure phosphorylation site occupancy

• Cell-based activation assays:

  • Overexpression of wild-type or mutant CDC25A in cells followed by analysis of CDK phosphorylation status

  • RNAi-mediated knockdown of CDC25A to assess the resulting impact on CDK activation

  • Use of specific CDC25 inhibitors

  • Analysis of CDK substrate phosphorylation as a readout of CDK activity

• Spatial activation analysis:

  • Immunofluorescence microscopy to track the location of active CDK-cyclin complexes using phospho-specific antibodies

  • Time-lapse imaging with fluorescent reporters of CDK activity

  • Studies have shown that active Cyclin B1/Cdk1 first appears on centrosomes before spreading to the cytoplasm and nucleus

• Structural studies:

  • Cryo-EM analysis of CDC25A in complex with CDK-cyclin substrates provides insights into the molecular mechanism of dephosphorylation

  • Mutagenesis of key residues identified in structural studies to validate their functional importance

• Cell synchronization experiments:

  • Synchronize cells at different cell cycle stages to analyze CDC25A-dependent CDK activation during specific transitions

  • Release cells from cell cycle blocks and monitor the kinetics of CDK activation in the presence or absence of CDC25A

• Biosensor approaches:

  • FRET-based biosensors can be used to monitor CDK activity in real-time in living cells

  • These approaches can reveal spatial and temporal dynamics of CDC25A-mediated CDK activation

By combining these approaches, researchers can build a comprehensive understanding of how CDC25A activates CDKs in different cellular contexts and cell cycle phases.

What are the most common technical challenges when working with CDC25A antibodies and how can they be addressed?

Researchers working with CDC25A antibodies frequently encounter several technical challenges that can be addressed with specific strategies:

• Cross-reactivity with other CDC25 isoforms:

  • Challenge: CDC25A, CDC25B, and CDC25C share sequence homology, potentially leading to cross-reactivity.

  • Solution: Validate antibody specificity using samples with siRNA knockdown of specific CDC25 isoforms . Use recombinant proteins as positive controls. Select antibodies raised against unique regions of CDC25A, particularly portions of the N-terminal regulatory domain which differs considerably between isoforms.

• Protein degradation during sample preparation:

  • Challenge: CDC25A has a short half-life due to rapid proteasomal degradation.

  • Solution: Include proteasome inhibitors (e.g., MG132) during sample preparation. Process samples quickly and maintain cold temperatures throughout. Add phosphatase inhibitors as CDC25A stability is regulated by phosphorylation.

• Low signal intensity:

  • Challenge: CDC25A is often expressed at relatively low levels in many cell types.

  • Solution: Increase protein loading for Western blots. Use signal amplification methods like TSA (tyramide signal amplification) for immunostaining. Consider using more sensitive detection methods such as enhanced chemiluminescence substrates or fluorescent detection systems .

• Variability in subcellular localization detection:

  • Challenge: Different fixation methods can affect the detected localization of CDC25A.

  • Solution: Compare multiple fixation methods (e.g., paraformaldehyde vs. methanol). Include co-staining with organelle markers. Use complementary approaches such as biochemical fractionation to confirm localization findings.

• Background signal in immunofluorescence:

  • Challenge: High background can obscure specific CDC25A signal.

  • Solution: Optimize blocking conditions (duration, blocking agent). Increase washing steps. Test different antibody dilutions. Consider using monovalent Fab fragments or use antigen adsorption controls.

• Phosphorylation-dependent epitope masking:

  • Challenge: Phosphorylation of CDC25A near the antibody epitope can mask recognition.

  • Solution: If studying phosphorylated forms, use phospho-specific antibodies. For total CDC25A detection, consider treating a control sample with lambda phosphatase to determine if dephosphorylation affects antibody recognition.

• Inconsistent results in co-immunoprecipitation:

  • Challenge: Capturing CDC25A-substrate interactions can be difficult.

  • Solution: Use mild detergents like CHAPS that better preserve protein-protein interactions . Consider crosslinking approaches to stabilize transient interactions. Optimize buffer conditions to maintain complex integrity.

How can CDC25A antibodies be used to investigate the relationship between cell cycle checkpoints and DNA damage response?

CDC25A antibodies are valuable tools for investigating the intricate relationship between cell cycle checkpoints and DNA damage response (DDR) through several experimental approaches:

• Monitoring CDC25A degradation after DNA damage:

  • CDC25A is rapidly degraded in response to DNA damage as part of checkpoint activation.

  • Use Western blotting with CDC25A antibodies to track protein levels at different time points after inducing DNA damage with agents such as UV irradiation, ionizing radiation, or genotoxic drugs.

  • Combine with proteasome inhibitors to determine if decreased levels are due to proteasomal degradation.

• Analyzing CDC25A phosphorylation in checkpoint response:

  • DNA damage leads to CDC25A phosphorylation by checkpoint kinases (Chk1/Chk2), marking it for degradation.

  • Use phospho-specific antibodies or mobility shift assays to detect phosphorylated CDC25A.

  • Perform immunoprecipitation with CDC25A antibodies followed by Western blotting with phospho-specific antibodies or mass spectrometry to identify specific phosphorylation sites.

• Subcellular localization studies:

  • DNA damage can alter CDC25A localization as part of checkpoint control.

  • Use immunofluorescence with CDC25A antibodies to track localization changes after DNA damage.

  • Perform biochemical fractionation followed by Western blotting to confirm localization findings.

• Checkpoint bypass studies:

  • Express phosphorylation-resistant CDC25A mutants and use CDC25A antibodies to confirm expression levels.

  • Analyze the consequences of maintaining CDC25A levels/activity during DNA damage by measuring CDK activity, cell cycle progression, and genomic instability.

• Kinetics of checkpoint recovery:

  • As cells repair DNA damage and recover from checkpoint arrest, CDC25A levels increase.

  • Use time-course experiments with CDC25A antibodies to monitor the reappearance of CDC25A during checkpoint recovery.

  • Correlate CDC25A levels with CDK activation status and cell cycle re-entry.

• Interactions with checkpoint mediators:

  • Use CDC25A antibodies for co-immunoprecipitation experiments to identify interactions with checkpoint mediators like 14-3-3 proteins, which regulate CDC25 localization .

  • Perform proximity ligation assays (PLA) to detect these interactions in situ.

• Checkpoint adaptation studies:

  • In cases of prolonged checkpoint activation, cells may eventually adapt and re-enter the cell cycle despite unrepaired damage.

  • Track CDC25A levels during checkpoint adaptation to determine if its re-expression correlates with adaptation.

• Combined analysis with other checkpoint regulators:

  • Use multicolor immunofluorescence with antibodies against CDC25A and other DDR components (γH2AX, 53BP1, pATM, etc.) to correlate CDC25A status with the activation state of the DDR.

These approaches provide mechanistic insights into how CDC25A regulation connects cell cycle control with genome integrity maintenance pathways.

What recent technical advances have improved the structural characterization of CDC25A interactions with substrates?

Recent technical advances have significantly enhanced our ability to characterize CDC25A interactions with its substrates at a structural level:

• Cryo-electron microscopy (cryo-EM) breakthroughs:

  • The recent cryo-EM structure of the CDK2-cyclin A-CDC25A complex at 2.91 Å resolution represents a significant technical achievement, as this ~86 kDa complex is one of the smallest asymmetric particles solved by cryo-EM to a resolution better than 3 Å .

  • Improved sample preparation techniques, including the use of CHAPS detergent, have been crucial for obtaining a wider variety of 2D class averages and overcoming preferential orientation issues that previously limited structural analysis .

  • Advanced particle picking methods, including both blob picking and Topaz picking approaches, have improved the identification of CDC25A-CDK-cyclin complexes in cryo-EM data .

• Methodological improvements in protein complex preparation:

  • Optimization of expression and purification protocols has enabled the isolation of stable CDC25A-CDK-cyclin complexes suitable for structural studies.

  • The ability to produce recombinant full-length CDC25A or functional catalytic domains with preserved activity has facilitated interaction studies.

  • Advances in protein engineering, such as the introduction of specific mutations or truncations, have helped stabilize these typically transient enzyme-substrate complexes.

• Integration of complementary structural techniques:

  • Combining cryo-EM with other structural methods such as X-ray crystallography, small-angle X-ray scattering (SAXS), and hydrogen-deuterium exchange mass spectrometry (HDX-MS) provides a more comprehensive view of CDC25A-substrate interactions.

  • These complementary approaches help validate key findings and can provide dynamic information not captured in static structures.

• Computational advances:

  • Improved image processing algorithms and classification methods have enhanced the resolution achievable with cryo-EM, particularly for smaller complexes like CDC25A-CDK-cyclin.

  • Molecular dynamics simulations can augment experimental structures by providing insights into the dynamic aspects of CDC25A-substrate interactions.

  • Advanced bioinformatic approaches help identify conserved interaction motifs and predict functional consequences of mutations.

These technical advances have revealed previously unknown features of CDC25A-substrate interactions, such as the newly identified C-terminal helix in CDC25A that binds at the CDK2-cyclin A interface . Such structural insights are crucial for understanding the molecular basis of CDC25A function and may inform the development of specific modulators of CDC25A activity for research and potentially therapeutic purposes.

What are the key considerations for researchers planning to use CDC25A antibodies in their studies?

Researchers planning to use CDC25A antibodies should consider several key factors to ensure successful and meaningful experiments:

• Experimental application matching: Select a CDC25A antibody specifically validated for your intended application (WB, IHC, IF/ICC) . An antibody that works well for Western blotting may not be optimal for immunofluorescence due to differences in epitope accessibility in denatured versus fixed proteins.

• Isoform specificity: Ensure the antibody specifically recognizes CDC25A without cross-reactivity to CDC25B or CDC25C, particularly when studying isoform-specific functions. Review the immunogen sequence and validation data carefully .

• Epitope location awareness: Consider where the antibody binds on CDC25A. Antibodies recognizing the catalytic domain may interfere with enzyme activity in functional assays, while those targeting the regulatory domain might be affected by post-translational modifications or protein-protein interactions.

• Species cross-reactivity: Verify the antibody's reactivity with CDC25A from your species of interest. While some antibodies recognize human, mouse, and rat CDC25A, others may have limited cross-species reactivity .

• Protocol optimization: Be prepared to optimize protocols for your specific experimental system, including antibody concentration, incubation conditions, buffer compositions, and detection methods .

• Appropriate controls: Include positive controls (cells/tissues known to express CDC25A), negative controls (CDC25A knockdown/knockout samples), and isotype controls to validate specificity and performance.

• Cell cycle status consideration: CDC25A expression and localization vary throughout the cell cycle. Consider cell synchronization techniques if studying phase-specific phenomena.

• Conjugation needs: Determine if a conjugated antibody is required for your application (e.g., flow cytometry, direct immunofluorescence). Many conjugation options are available, including various fluorophores, enzymes, and biotin .

• Validation strategy: Plan to validate key findings with complementary approaches, such as using multiple antibodies targeting different epitopes, genetic approaches to manipulate CDC25A expression, or alternative techniques to confirm antibody-based observations.